Recombinant human erythropoietin: factors to consider in cost-benefit analysis.
Sheingold
S H
SH
Churchill
D N
DN
Muirhead
N
N
Laupacis
A
A
D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D001803:Blood Transfusion / Q000191:economics; D003362:Cost-Benefit Analysis; D004921:Erythropoietin / Q000627:therapeutic use*; D006801:Humans; D007349:Insurance, Health, Reimbursement; D007676:Kidney Failure, Chronic / Q000150:complications / Q000191:economics*; D011788:Quality of Life; D011994:Recombinant Proteins / Q000627:therapeutic use; D006435:Renal Dialysis; D012959:Socioeconomic Factors
D011994:Recombinant Proteins; D004921:Erythropoietin